|
|
Vaccine Detail
|
Pvs25-IMX313/Matrix-M1 |
| Vaccine Information |
- Vaccine Name: Pvs25-IMX313/Matrix-M1
- Target Pathogen: Plasmodium spp.
- Target Disease: Malaria
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Antigen: Pvs25 (Minassian et al., 2022): P.vivax surface protein 25, composed of four cysteine-rich epidermal growth factor–like domains expressed on the surface of zygotes and ookinetes of P. vivax (Arevalo-Herrera et al., 2005).
- Pvs25
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Host Strain: healthy adults in United Kingdom (Minassian et al., 2022)
- Vaccination Protocol: Non-randomised, Phase Ia study, not started
Volunteers will receive 1) three doses of 10 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56, 2) three doses of 50 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56, or 3) two doses of 50 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0 and 28, followed by one dose of 10 µg Pvs25-IMX313 in 50 µg Matrix-M1 on day 56 (Minassian et al., 2022)
|
| References |
Arevalo-Herrera et al., 2005: Arevalo-Herrera M, Solarte Y, Yasnot MF, Castellanos A, Rincon A, Saul A, Mu J, Long C, Miller L, Herrera S. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein. The American journal of tropical medicine and hygiene. 2005 Nov; 73(5 Suppl); 32-7. [PubMed: 16291764].
Minassian et al., 2022: Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine [https://clinicaltrials.gov/ct2/show/NCT05270265?term=vaccine&cond=Malaria%2C+Vivax&draw=2&rank=4]
|
|
